Antibiotics

Research presented at the 47th Critical Care Congress reveals that PCT-guided antibiotic cessation in critically ill patients resulted in reduced mortality.

Marin H. Kollef, MD, discusses the strongest approach for treating Pseudomonas infections.

Scientists from the NIH and Rutgers New Jersey Medical School are in the process of developing a promising alternative to antibiotic treatments for multidrug-resistant Klebsiella pneumoniae bacteria.

CARB-X, the international partnership between governmental and charitable groups in the United States and the United Kingdom, has announced new funding for the development of new antibiotics to fight drug-resistant bacteria.

High prescribing continues despite the fact that heavy use of these agents can facilitate the development of multidrug-resistant bacteria and tendon, muscle, joint, and central nervous system damage.

Lingering historical concerns have led to inconsistent practices in antibiotic prophylaxis in this population.

Poignant study adds to the growing body of literature that points toward individualizing duration of therapy for each patient.

Dr. Richard Vickers, discusses C. difficile rates in the United Kingdom.

One successful model takes an engineering approach to patient safety outcomes focusing on work system improvements.

FDA recommends that health care providers practice caution before prescribing clarithromycin to patients with heart disease due to potentially fatal long-term risks.

One agency estimates that at least 50% of all antibiotic prescriptions written in the United States do not fall under currently accepted practice guidelines.

Efforts to curb antimicrobial resistance have hit a brick wall in India, where new research finds unapproved drug combinations are rampant.

Dr. Richard Vickers, discusses what the next steps are for Summit Therapeutic’s ridinilazole.

Marin H. Kollef, MD, discusses what to consider when calling for cultures.